Nonetheless, early CD8+ T cell infiltration in PRAD and persistence of potential DCs in late-stage NEPC in this model suggest that deeper analysis may be informative in addressing the disappointing clinical results seen with conventional immune checkpoint blockade therapy in prostate cancer. The gene discussed is CD8A; the disease is prostate carcinoma.